Barclays Maintains Overweight on Claritev, Raises Price Target to $40
Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
Read original at benzingaStocks · News reference
Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 1:05 PM
- Checked
- Aug 17, 2026, 1:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30
Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and raises the price target from $22 to $30.
Read original at benzingaClaritev Analysts Raise Their Forecasts Following Q2 Earnings
CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.
Read original at benzingaMarpai Q2 EPS $(0.18) Up From $(0.28) YoY, Sales $4.166M Down From $4.656M YoY
Marpai (OTC:MRAI) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported $4.166 million in sales this
Read original at benzinga8-K filing — Marpai, Inc. (MRAI)
Filed: 2026-07-31 AccNo: 0001213900-26-084129 Size: 687 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar